Time until incident dementia among Medicare beneficiaries using centrally acting or non-centrally acting ACE inhibitors

Pharmacoepidemiology and Drug Safety

Volumn 22, Issue 6, 2013, Pages 641-648

  Hebert, Paul L ^a,b   Mcbean, Alexander Marshall ^c   O'Connor, Heidi ^c   Frank, Barbara ^c   Good, Charles ^c   Maciejewski, Matthew L ^d,e  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d DURHAM VA MEDICAL CENTER   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ACE inhibitor; Alzheimer's; Centrally active; Dementia; Hypertension; Medicare; Pharmacoepidemiology

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE AND RELATED DEMENTIA; ARTICLE; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICARE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENILE DEMENTIA; TIME;

AGED; ALZHEIMER DISEASE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD-BRAIN BARRIER; COHORT STUDIES; DEMENTIA; FEMALE; HUMANS; INCIDENCE; MALE; MEDICARE; PREVALENCE; RETROSPECTIVE STUDIES; TIME FACTORS; UNITED STATES;

EID: 84878795536     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3449     Document Type: Article

References (30)

1. Lin PJ, Kaufer DI, Maciejewski ML, Ganguly R, Paul JE, Biddle AK. An examination of Alzheimer's disease case definitions using Medicare claims and survey data. Alzheimers Dement 2010; 6(4): 334-341.
2. Aslam F, Haque A, Agostini JV, Wang Y, Foody JM. Hypertension prevalence and prescribing trends in older US adults: 1999-2004. J Clin Hypertens (Greenwich) 2010; 12(2): 75-81.
3. McGuinness B, Todd S, Passmore P, Bullock R. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst Rev 2009(4): CD004034.
4. Yamada K, Horita T, Takayama M, et al. Effect of a centrally active angiotensin converting enzyme inhibitor, perindopril, on cognitive performance in chronic cerebral hypo-perfusion rats. Brain Res 2010; 1421: 110-120.
5. Dong YF, Kataoka K, Tokutomi Y, et al. Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer's disease. FASEB J 2011; 25(9): 2911-2920.
6. Yamada K, Horita T, Takayama M, et al. Effect of a centrally active angiotensin converting enzyme inhibitor, perindopril, on cognitive performance in chronic cerebral hypo-perfusion rats. Brain Res 2011; 1421: 110-120.
7. Danielyan L, Klein R, Hanson LR, et al. Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease. Rejuvenation Res 2010; 13(2-3): 195-201.
8. Washida K, Ihara M, Nishio K, et al. Nonhypotensive dose of telmisartan attenuates cognitive impairment partially due to peroxisome proliferator-activated receptor-gamma activation in mice with chronic cerebral hypoperfusion. Stroke 2010; 41(8): 1798-1806.
9. Sink KM, Leng X, Williamson J, et al. Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study. Arch Intern Med 2009; 169(13): 1195-1202.
10. Li NC, Lee A, Whitmer RA, et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010; 340: b5465.
11. Maxwell CJ, Hogan DB. Antihypertensive agents and prevention of dementia. BMJ 2010; 340: b5409.
12. Opie LH. Inhibition of the cerebral renin-angiotensin system to limit cognitive decline in elderly hypertensive persons. Cardiovasc Drugs Ther 2011; 25(4): 277-279.
13. Hennessy S, Kimmel SE. Is improved survival a class effect of angiotensin-converting enzyme inhibitors? Ann Intern Med 2004; 141(2): 157-158.
14. Warehouse CC. http://www.ccwdata.org/cs/groups/public/documents/document/ccw_conditioncategories2011.pdf. 2012. [1 June 2012].
15. Putter H, Sasako M, Hartgrink HH, van de Velde CJ, van Houwelingen JC. Long-term survival with non-proportional hazards: results from the Dutch Gastric Cancer Trial. Stat Med 2005; 24(18): 2807-2821.
16. Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol 2011; 64(7): 749-759.
17. Austin PC. The performance of different propensity-score methods for estimating relative risks. J Clin Epidemiol 2008; 61(6): 537-545.
18. Austin PC. Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many-to-one matching on the propensity score. Am J Epidemiol 2010; 172(9): 1092-1097.
19. Newhouse JP, McClellan M. Econometrics in outcomes research: the use of instrumental variables. Annu Rev Public Health 1998; 19: 17-34.
20. Brookhart MA, Wang PS, Solomon DH, Schneeweiss S. Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology 2006; 17(3): 268-275.
21. Hennessy S, Leonard CE, Palumbo CM, Shi X, Ten Have TR. Instantaneous preference was a stronger instrumental variable than 3- and 6-month prescribing preference for NSAIDs. J Clin Epidemiol 2008; 61(12): 1285-1288.
22. Fang G, Brooks JM, Chrischilles EA. A new method to isolate local-area practice styles in prescription use as the basis for instrumental variables in comparative effectiveness research. Med Care 2010; 48(8): 710-717.
23. Terza JV, Basu A, Rathouz PJ. Two-stage residual inclusion estimation: addressing endogeneity in health econometric modeling. J Health Econ 2008; 27(3): 531-543.
24. Ligthart SA, Moll van Charante EP, Van Gool WA, Richard E. Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review. Vasc Health Risk Manag 2010; 6: 775-785.
25. Haag MDM, Hofman A, Koudstaal PJ, Breteler MMB, Stricker BHC. Duration of antihypertensive drug use and risk of dementia. Neurology 2009; 72(20): 1727-1734.
26. Yoon S, Burt V, Carroll L. Hypertension among Adults in the United States, 2009-2010. National Center for Health Statistics: Hyattsville, MD; 2012.
27. Yoon S, Ostchega Y, Louis T. Recent Trends in the Prevalence of High Blood Pressure and Its Treatment and Control, 1999-2008. National Center for Health Statistics: Hyattsville, MD; 2010.
28. Taylor DH, Jr, Fillenbaum GG, Ezell ME. The accuracy of medicare claims data in identifying Alzheimer's disease. J Clin Epidemiol 2002; 55(9): 929-937.
29. Sonnen JA, Santa Cruz K, Hemmy LS, et al. Ecology of the aging human brain. Arch Neurol 2011; 68(8): 1049-1056.
30. Sonnen JA, Larson EB, Crane PK, et al. Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol 2007; 62(4): 406-413.